Scholars Central

Conference abstract

Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man

Authors: Shimon Slavin

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Engraftment of T cells or donor lymphocyte infusion (DLI) following allogeneic stem cell transplantation (SCT) results in graft-vs.-tumor effects (GVT) but is accompanied by acute and chronic graft-vs.-host disease (GVHD). GVT effects post SCT can be accomplished by IL-2 activated natural killer (NK) cells prepared by negative selection of CD3+ T cells or by positive selection of CD56+ NK cells. Interestingly, mismatched NK cells are much more effective GVT inducers, yet they cause no GVHD. Based on animal experiments using murine models of B cell leukemia (BCL1) and metastatic breast cancer (4T1) we have documented that GVT effects mediated by intentionally mismatched IL-2 activated killer cells (IMAK), including T, NK & NKT cells, can result in cure when applied at the stage of minimal residual disease (MRD) following conventional or high dose chemotherapy and SCT. Using IMAK with no prior SCT results in consistent rejection of alloreactive donor lymphocytes within one week and as such GVHD is prevented while malignant cells are being attacked as long as donor lymphocytes circulate. More selective GVT effects induced by IMAK against residual malignant cells can be accomplished by targeting killer T, NK & NKT cells against tumor cells by monoclonal or bispecific antibodies against over-expressed antigens (e.g. Erbitux, Avastin or Catumaxomab for solid tumors or MabThera for B cell malignancies). In conclusion, based on observations in mice and man, IMAK provides a safe treatment for patients with residual malignant cells resistant to available anti-cancer agents while avoiding the risk of GVHD.

Subjects

Haematology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Blood Disorders & Transfusion.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Blood Disorders & Transfusion
  • SubjectHaematology
  • BylineArticles whose byline prints “Shimon Slavin”